For Immediate ReleaseChicago, IL – June 10, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva Pharmaceuticals TEVA and Viatris VTRS.Industry: Generic DrugsLink: https://www.zacks.com/commentary/2490523/3-generic-drug-stocks-to-watch-amid-pricing-pressure-tariff-threatsGeneric...
Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing...
/CNW/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch in Canada of Gen-Clozapine orally disintegrating tablets (ODT)...
/Viatris%20Inc%20logo%20on%20phone-by%20rafapress%20via%20Shutterstock.jpg)
Viatris has underperformed the broader market over the past year, and analysts remain skeptical of the stock’s future potential.
2 S&P 500 Stocks Worth Investigating and 1 to Avoid
/Viatris%20Inc%20logo%20on%20building-by%20SSKH-Pictures%20via%20Shutterstock.jpg)
Viatris is scheduled to report its first-quarter results next month, and analysts expect a double-digit earnings drop.
Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest
3 Reasons VTRS is Risky and 1 Stock to Buy Instead
